MINY ANOMALY SCAN – ultrasound (the price of ultrasound examination in the Polyclinic is 220,00 kn)
It is an ultrasound screening for foetal chromosomal abnormalities and part of structural anomalies already during the first trimester of pregnancy. Chromosomal screening should be done during 11-13+6 week of pregnancy, but since in the 12th week a part of structural anomalies becomes visible, in the Polyclinic is recommended to perform the screening when the pregnancy has reached the period of 12 weeks. Then is possible to see up to 50% of structural anomalies.
- Foetal nuchal translucency (NT or NN)- measuring space of foetal nuchal fold – that space in foetus with Down syndrome- T 21, significantly grows. The strongest independent ultrasound marker for Down syndrome screening (detection rate 77%) and it indicates possible cardiac anomalies, TORCH infections + parvovirus and lymphatic system anomalies.
- Nasal bone of the foetus NB
- Color Doppler examination- DV Ductus venosus of the foetus, TR tricuspid regurgitation and vena cava inf S, D and A waves
- Foetal heart rate FHR
COMBINED TEST- ultrasound + laboratory (the price of the combined test in the Polyclinic is 762,50 kn)
11 weeks to 13+6 – optimally after 12th week of pregnancy
Measuring of nuchal fold + serum markers (PAPP-A and f-bHCG) during the 12th week sensitivity of the test up to 90% (rate of detection)- compared with a Triple test together with mother’s age which is 65%
Expanded combined test with ultrasound multi-markers
NT+ NK + DV + TR + FHR + PAPP-A + f-BHCG – test sensitivity up to 98%
At risk 1:50 – 1:100 and more invasive prenatal diagnostic CVS is indicated; at risk 1:100 – 1:1000, recommendation is to do other early ultrasound markers, repeat ultrasound in the 14th week due to regression evaluation NT, Triple test in 16th week, genetic screening of ba anomaly in the 19th week and opt for early amniocenteses and at very low risk, less than 1:1000 do usual routine examinations. From now on, at higher risk in combined test, is possible to do non-invasive diagnostic from mother’s blood- NIFTY test and in that way avoid risks of early amniocenteses or CVS.
One of the NIPT tests can be done from now on in the Polyclinic Arcadia- the test from mother’s blood detects free foetal extracellular DNA.
Prices since Nov 1st 2016
- NIFTY of basic trisomy (21, 18 and 13) 3499 kn (465€)
- NIFTY of standard trisomy (21,18 and 13) + aneuploidy of the sex chromosomes + gender 3899 kn (520 €)
- NIFTY Plus trisomy (21,18 and 13) + trisomy (9, 16, 22) + aneuploidy of the sex chromosomes + microdeletions – gender 4399 kn (590 €)
The test detects and sequences extracellular foetal DNA from the sample of mother’s blood. In that way, with high reliability, it detects Dow syndrome (trisomy 21) and other foetal genetic anomalies in the period between 10+0 weeks of pregnancy until the penultimate day of the due date.
- with pregnant women with abnormal ultrasound result
- with pregnant women whose combined screening indicates high or moderately high risk
- with pregnant women with a burdened family anamnesis as well as
- With all pregnant women who want that
NIFTY™ is a non-invasive prenatal test (NIPT, English- Non-Invasive Prenatal Test) which serves for detecting Down syndrome and other chromosomal abnormalities which are the result of excess or lack of chromosomes and that is genetic information in the baby’s DNA. In order to perform NIFTY™ test, only a small sample of mother’s blood is necessary and the test can already be done from the 10th week of pregnancy. You will get the test results within 6 to 10 days.
NIFTY™ has greater accuracy compared to standard screening tests and unlike invasive procedures such as amniocentesis, NIFTY does not cause any risk of miscarriage and is completely safe for both mother and the baby.
Unit March 2016, more than 1 000 000 samples all around the world were analysed by NIFTY™ test.
NIFTY™ also offers the possibilities of detecting other genetic disorders such as disturbance of number of sex chromosomes, chromosomal trisomy 9, 16 and 22, as well as certain microdeletions. If you want it, the NIFTY™ test can detect your baby’s gender too.
NIFTY detects three most common disorders which are the result of chromosomal trisomy: Down syndrome, Edwards syndrome and Patau syndrome. Independent research for test validation, including the world’s greatest research about NIPT test use in clinical practice which included around 147 000 women participants, showed that the accuracy of detecting these trisomies is higher than 99%.
With this test, the number of unnecessary amniocentesis is reduced by 90%, and with that the number of complications- miscarriages after the procedure- is reduced too.
Without screening, 0.6% new-born children would have chromosomal diseases, 2% structural anomalies and 0.08% genetic diseases.